Last quarter (Q3 2024), Haemonetics's total revenue was $336.25M, an increase of 10.14% from the same quarter last year. In Q3, Haemonetics's net income was $31.24M. See Haemonetics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Apr 23	Apr 22	Mar 22	Mar 21	Mar 20
Total Revenue	$ 965.76M	$ 1.17B	-	$ 993.20M	$ 870.46M	$ 988.48M
Cost of Revenue	$ 450.12M	$ 553.56M	$ 487.69M	$ 487.69M	$ 472.63M	$ 503.97M
Gross Profit	$ 515.64M	$ 615.10M	$ -487.69M	$ 505.50M	$ 397.84M	$ 484.51M
Operating Expense	$ 380.70M	$ 459.06M	$ 433.78M	$ 433.78M	$ 339.88M	$ 338.65M
Operating Income	$ 149.89M	$ -1.01B	$ -921.47M	$ 71.72M	$ 57.96M	$ 145.87M
Net Non Operating Interest Income Expense	-	$ 13.00M	$ 5.80M	$ -17.12M	$ -16.83M	$ -16.20M
Other Income Expense	$ 6.49M	$ -1.15B	$ -985.10M	$ 9.03M	$ 31.78M	$ -42.52M
Pretax Income	$ 128.45M	$ 141.40M	$ 63.63M	$ 63.63M	$ 72.91M	$ 87.15M
Tax Provision	$ 31.20M	$ 26.00M	$ 20.30M	$ 20.25M	$ -6.56M	$ 10.63M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ 111.68M	$ 115.40M	$ 43.33M	$ 43.38M	$ 79.47M	$ 76.53M
Basic EPS	-	-	-	$ 0.85	$ 1.57	$ 1.51
Diluted EPS	-	-	-	$ 0.84	$ 1.55	$ 1.48
Basic Average Shares	-	-	-	$ 51.05M	$ 50.69M	$ 50.69M
Diluted Average Shares	-	-	-	$ 51.35M	$ 51.29M	$ 51.81M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	$ 2.35	$ 3.31
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 830.83M	$ 1.01B	$ 921.47M	$ 921.47M	$ 812.50M	$ 842.61M
Net Income From Continuing And Discontinued Operation	$ 97.19M	$ 115.40M	$ 43.33M	$ 43.38M	$ 79.47M	$ 76.53M
Normalized Income	$ 136.19M	-	-	$ 37.22M	$ 56.27M	$ 113.86M
Interest Expense	-	-	-	$ 17.12M	$ 16.83M	$ 16.20M
EBIT	$ 128.45M	$ 128.40M	$ 57.83M	$ 80.75M	$ 89.75M	$ 103.35M
EBITDA	$ 200.42M	$ 35.10M	$ -39.92M	$ 178.50M	$ 174.03M	$ 213.64M

Currency in USD

Haemonetics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing